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Background: In Haiti where chloroquine (CQ) is widely used for malaria treatment, reports of resistance are scarce.
However, recent identification of CQ resistance genotypes in one site is suggestive of an emerging problem.
Additional studies are needed to evaluate genetic mutations associated with CQ resistance, especially in the
Plasmodium falciparum multi-drug resistance-1 gene (pfmdr1) while expanding the already available information
on P. falciparum CQ transporter gene (pfcrt) in Haiti.
Methods: Blood samples were collected on Whatman filter cards (FTA) from eight clinics spread across Haiti.
Following the confirmation of P. falciparum in the samples, PCR protocols were used to amplify regions of pfmdr1and
pfcrt codons of interest, (86, 184, 1034, 1042, and 1246) and (72-76), respectively. Sequencing and site-specific restriction
enzyme digestions were used to analyse these DNA fragments for the presence of single nucleotide polymorphisms
(SNPs) known to confer resistance to anti-malarial drugs.
Results: P. falciparum infection was confirmed in160 samples by amplifying a segment of the P. falciparum 18S small
subunit ribosomal RNA gene (pfssurrna). The sequence of pfmdr1 in 54 of these samples was determined between
codons 86,184 codons 1034, 1042 and 1246. No sequence differences from that of the NF54 clone 3D7 were found
among the 54 samples except at codon 184, where a non-silent mutation was found in all samples predicted to alter
the amino acid sequence replacing tyrosine with phenylalanine (Y184F). This altered sequence was also confirmed by
restriction enzyme digestion. The sequence of pfmdr1 at codons 86, 184, 1034 and 1042 encoded the NFSN haplotype.
The sequence of pfcrt codons 72-76 from 79 samples was determined and found to encode CVMNK, consistent with a
CQ sensitive genotype.
Conclusion: The presence of the Y184F mutation in pfmdr1 of P. falciparum parasites in Haiti may have implications for
resistance to antimalarial drugs. The absence of mutation in pfcrt at codon 76 among 79 isolates tested suggests that
sensitivity to CQ in Haiti remains common. Wide-spread screening of the pfmdr1 and pfcrt especially among patients
experiencing treatment failure may be a useful tool in early detection of the emergence of antimalarial drug resistance
in Haiti.
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An estimated 30,000 cases of malaria infections are
reported annually in Haiti [1,2], where transmission is
hypo-endemic with sporadic epidemics fueled by heavy
rainfall. Malaria infections in Haiti are dominantly caused
by Plasmodium falciparum [3,4]. Chloroquine (CQ) has
been in use as an anti-malarial since the 1950s [5], and is
currently used extensively in the treatment of malaria
in Haiti [1]. Recently, a national malaria treatment policy
revision added single dose primaquine to target gameto-
cytes [1]. Despite long-term use, there are scarce reports
of CQ-resistant P. falciparum malaria in Haiti [6-8].
However, the recent reports of CQ-resistant P. falciparum
parasites harbouring known resistant alleles of pfcrt [9,10]
are alarming and could present serious challenges to
clinical management of malaria in Haiti and diminish
prospects for its elimination from Hispaniola (the
Caribbean island where both Haiti and the Dominican
Republic are located).
Research studies conducted more than three decades
ago found only CQ sensitive P. falciparum strains [6,7],
but very few follow-up studies have been conducted
during the intervening years. In the recent past, a few
studies identified the CQ-resistance-associated K76T
mutation in the pfcrt at a very low prevalence in samples
from the Artibonite valley, from Leogane, and from
travellers returning from Haiti [8-10]. The potential
role of resistant alleles of pfmdr1 in CQ resistance in
Haiti has yet to be investigated. In addition, there is a
need to screen for the CQ resistance-associated pfcrt
and pfmdr1 alleles in other parts of Haiti.
Single nucleotide polymorphisms (SNPs) in the pfmdr1
have been associated with resistance to CQ and other
anti-malarial drugs including amodiaquine (AQ) and
artemether-lumefantrine (AL). The P. falciparum glyco-
protein homologue-1 found in the digestive vacuole of
the malaria parasites is encoded by pfmdr1 gene [11].
CQ diffuses to parasite food vacuole (FV) membrane
neutrally where it protonates by acids present, which
prevents free diffusion out the vacuole and results in
accumulation of CQ in sensitive parasites. In CQ resistant
parasites, changes in FV membrane proteins encoded
by pfcrt and pfmdr1genes are thought to play a role in
reducing accumulation of drug inside the vacuole [11-14].
The role played by pfmdr1 mutations (N86Y, Y184F,
S1034C and D1246Y) in mediating in vivo and in vitro
CQ resistance has received a lot of research interest
[13,15-23]. No previous reports have described alleles
of pfmdr1 that may be associated with anti-malarial
drug resistance in Haiti. Therefore, this research study
evaluated in Haiti the mutations in pfmdr1 that in other
regions of the world are associated with resistance to
CQ and expanded the surveillance locations in Haiti for




The sites where the samples originated are located in
Port-au-Prince, Artibonite, North Cap Haitian, Leogane,
Hinche and Jacmel (Figure 1). All sites are rural com-
munities except the Port-au-Prince site, which is near
the international airport. All locations suffer drastically
from poor infrastructural facilities, which is common in
Haiti. The average temperature in these sites ranges
from (22°C-35°C) all year round [24] which favors malaria
vector breeding and consequently malaria transmission.
Peak rainfall occurs between November and January [25],
and the majority of malaria cases were sampled during
this period.
Sample collection
Plasmodium falciparum malaria infected blood samples
were collected by finger prick and preserved as dried blood
spots (DBS) on FTA cards (Whatman GE Healthcare, MA,
USA) between May 2010 and June 2012. Samples were
obtained from patients attending study clinics, meeting
the inclusion criteria (any patient above the age of two
year old with malaria-like symptoms) who tested posi-
tive with rapid diagnostic test (CareStat™First Response
Malaria Ag pLDH/HRP2 Combo card, Premier Medical
Corporation, India) and microscopy for P. falciparum
and agreed to sign a consent form. All patients received
treatment according to the Haitian approved standard
of care available at the clinics. The Haiti Ethical Review
Board, University of Florida Institutional Review Board
and the Office of Research Protections, US Army Medical
Research and Material Command approved this study.
DNA extraction
Plasmodium falciparum DNA was extracted from the DBS
with a methanol extraction wash protocol as previously
described [26,27]. A single disc 3 mm in diameter was
punched from the DBS and placed in a 0.2 ml micro-
centrifuge tube. A volume of 100 μl of absolute methanol
was added and the tube incubated at room temperature for
15 min. Methanol was then decanted and the 3 mm disc
left to air dry for 30 min. Sixty-five microlitres of sterile
DNA-free grade water was then added to the dried disc, ag-
itated slightly and then heated to 97°C for 30 min. The tube
was then centrifuged at low speed and the supernatant
stored at −20°C for use in the PCR amplification protocol.
Detection of Plasmodium falciparum and amplification of
pfmdr1 by PCR
All samples were PCR tested to confirm the presence of
P. falciparum by amplifying the small subunit ribosomal
Figure 1 Map of Haiti showing sampling sites.
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falciparum with a one-step PCR as previously described
[10]. Confirmed P. falciparum positive samples were
subsequently used for amplification of segments of pfmdr1
encoding five codons of interest; 86, 184, 1034, 1042 and
1246 using a nested PCR protocol as previously described
[28]. All primer sequences used to amplify segments of
pfmdr1 are listed in Table 1. All PCR reactions included
the following reagents: 1x Taq PCR Master Mix, 0.2 mM
dNTPs, 0.75 mM MgCl2, and 0.2 μM of each primer.
The temperature protocol used for each reaction were as
follows: one cycle at 94°C for 2 minutes, an amplification
for 35 cycles (94°C for 30 sec, 45°C for 1 min, and 72°C
for 1 min) and a final extension at 72°C for 5 min. Two
microlitres of the product of the initial PCR was used as a
template for the nested second PCR reaction in all regions.
The products of the nested PCR were electrophoresed inTable 1 The PCR amplification primers list for pfmr1 and pfcrt
Gene PCR step Primer
pfmdr1 Nest 1 dr2 5
dr3 5
Nest 2 A4 5-TGTTGA
A2 5-GTCAAA
Nest 1 dr5 5-G
dr6 5
Nest 2 1034f 5-AGAATTA
1042r 5-AATGGA
1246f 5-ATGATCAC
pfcrt Pfcrt F1 5-CC
Pfcrt R2 5-AT2% agarose gels, stained with ethidium bromide (EtBr) and
visualized with a BioRad Transluminator (Universal Hood
II). Amplification products were used in restriction digest
analysis and sequenced as described below.
Restriction enzyme digestion for pfmdr1 mutations
The pfmdr1 amplification products were subjected to
restriction enzyme digestion. The restriction enzymes used
included Apo I/Afl III, Dra I, Dde I, AseI and EcoRV for
analysis of sequences at codons 86, 184, 1034, 1042 and
1246, respectively. All enzymes were purchased from New
England Biolabs (Ipswich, MA, USA). Technique was
performed as previously described [28,29]. Digestion was
carried out according to manufacturer instructions. The
product of digestion was resolved on a 2.5% agarose gel
and visualized with BioRad Transilluminator (Universal
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Samples positive for pfssurrna were used to amplify codons
72–76 of pfcrt gene as previously described [10,30]. A
one-step PCR was carried out using Phusion flash high
fidelity master mix from (New England Biolabs, Ipswich,
MA,USA) with a 25 μl final volume of PCR reaction
composed of 1x PCR Master Mix containing 0.2 mM
dNTPs, 0.5 μM each primer, 2.5 mM MgCl2, and 1 μl
of DNA extract. The cycling temperature protocol used
was: two cycles at 95°C for 5 min, amplification for
40 cycles (94°C for 30 sec, 60°C for 30 sec, and 72°C for
30 sec) and a final extension at 72°C for 10 min. Products
of amplification were then electrophoresed on 2% agar-
ose gel, stained with EtBr and visualized with BioRad
Transilluminator (Universal Hood II).
Sequencing and alignment
Amplified segments of pfmdr1 and pfcrt were sequenced
by the Sanger chain-termination method to determine
polymorphic sites associated with CQ or other anti-
malarial resistance. Sequencing was done on a Biosystem
3730 Genetic Analyzer at the University of Florida’s
Interdisciplinary Center for Biotechnology Research DNA
Sequencing Core Laboratory. All sequences results were
aligned to P. falciparum 3D7 pfmdr1and pfcrt sequences.
[GenBank: NC_004326.1 and NC_004328.2] respectively.
Results
A total of 375 microscopy-confirmed positive samples
for P. falciparum were collected for analysis by PCR. A
segment of the pfssurrna gene was successfully amplified
from160 of these samples. One or more segments of
interest from the pfmdr1 gene were successfully amplified
for sequence analysis from 54 samples. No mutations were
detected in codons 86, 1034, 1042 and 1246 among the
samples in which codons were successfully amplified.
However, mutations were found at codon 184 (Y→ F) in
all the samples in which the codon successfully amplified
which was further confirmed by restriction enzyme
digestion. The number of samples that successfullyTable 2 Presents summary of PCR amplification results and g
number of samples amplified for different genes pfssurrna, p
different codons of pfmdr1







Port-au-Prince 251 70 39 2
Leogane 40 39 17 8
Cap Haitian 10 2 3 0
L’Cay Jacmel 17 16 15 1
Artibonite 50 26 3 2
Nippes 7 7 2 2
Total 375 160 79 5amplified for each codon per site is shown in Table 2.
Thirty-eight samples that amplified at codons 86, 184,
1034 and 1042 were all NFSN haplotype. In the analysis
of pfcrt, the polymorphic region associated with CQ resist-
ance alleles, encompassing codons 72–76, was successfully
amplified from79 samples. No mutations were detected
with all samples expressing the wild type sequence
CVMNK. The intersection of samples from which both
alleles–pfcrt and pfmdr1- successfully amplified were 50.
Discussion
Although this study was limited by small sample size,
it provides preliminary information about the pfmdr1
alleles in Haiti and adds additional data on pfcrt alleles
in parasites from both previously sampled regions of
Haiti and from regions not previously sampled. This
study is the first to examine in Haiti the pfmdr1 genetic
mutations linked to anti-malarial drug resistance in other
regions of the world. This study found neither the K76T
mutation in pfcrt nor the N86Y, S1034C, N1042D or
D1246Y mutations in pfmdr1, that have been reported
to confer resistance to CQ [22,23,31-33]. The absence of
mutations at codons 1034 and 1042 in pfmdr1 suggests
that the P. falciparum parasites analysed in this study
likely remain sensitive to mefloquine [34] and AL [35].
Interestingly, all the samples tested had a Y− > F mutation
in codon 184 in pfmdr1. The widespread occurrence
of this single mutation in pfmdr1 is not unique in the
literature [36,37]. Previous studies of clinical isolates of P.
falciparum in Cambodia reported a similar widespread
occurrence of single point mutations, and the mutation
resulting in the Y184F mutation was predominant over
other pfmdr1 mutations [38].
Although the Y184F mutation in pfmdr1 has been
associated mainly with low level resistance to AL [39],
there is no consensus in the literature for its role in
CQ resistance [28,34,40]. In a previous study [15], the
Y184F polymorphism was shown to play a role in CQ
resistance in close association with the K76T mutation
in pfcrt. The Y184F mutation is thought to alter theeographic distribution of samples collected in the study,
fcrt, and differential data on no. of samples amplified for
86-184 Codon 1034-1042 Codon 1246 No. of samples amplified
for codons 86-1042
9 27 8 23
11 1 4
1 0 0
3 9 0 8
2 0 1
3 0 2
4 53 9 38
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efficacy. The absence of the K76T mutations in the study
sample indicates that the Y184F mutation in pfmdr1 is
rarely found in Haiti in combination with K76T in pfcrt.
Although this pfmdr1 allele may not alone increase CQ
resistance, it’s high prevalence could have an impact if
the frequency of the pfcrt K76T allele were to increase
in Haiti [8]. Other studies have shown a modification
of resistance to AL in P. falciparum with the Y184F
mutation under a N86Y and D1246Y background [36].
The absence of N86Y, S1034C, N1042D or D1246Y in
pfmdr1 alleles in this study sustains CQ or AL sensitivity
in Haiti. Therefore, the findings would seem to indicate
that the presence of the Y184F mutation alone would
not contribute greatly to anti-malarial resistance in Haiti
in the absence of wide spread K76T mutations in pfcrt
or additional mutations in pfmdr1. Routine molecular
surveillance of the anti-malarial drug resistance genes
in Haiti combined with in vitro drug sensitivity studies are
needed to ascertain the sensitivity of Haitian P. falciparum
strains to the major anti-malarial medications in use in
Haiti and other parts of world.
The recent reports of CQ resistance genotypes in Haiti
are alarming for public health officials in Haiti and
concerted efforts are needed to monitor the anti-malaria
drug resistance genotypes in Haiti. The results of this
study have provided background data on pfmdr1, which
may be referenced in discussions of future P. falciparum
anti-malarial resistance patterns in Haiti. This study also
provides additional data on the prevalence of the pfcrt
K76T allele in Haiti, but additional studies are needed to
increase the sample size and provide an accurate estimate
for K76T allele prevalence and distribution. Nonetheless,
the findings in this study have increased the knowledge
of two important anti-malaria drug resistance markers
in Haiti, where widespread drug resistance has not yet
been observed.
Study limitations
The small sample size is indeed the largest limitation of
this study, however due to the difficulty of the study
initiation; proper sample storage for the FTA cards was
lacking which affected the quality of DNA. The study
lack adequate sample distribution, were some sites
failed to enroll sufficient number of patients, this can
be attributed to change in site administration which
affected the study enrollment.
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